Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,873 shares of the medical research company's stock after selling 1,014 shares during the period. Kayne Anderson Rudnick Investment Management LLC's holdings in Thermo Fisher Scientific were worth $9,299,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barrett & Company Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth $28,000. FPC Investment Advisory Inc. purchased a new position in Thermo Fisher Scientific in the fourth quarter worth about $28,000. Pillar Financial Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Missouri Trust & Investment Co purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Down 1.2 %

TMO stock traded down $5.07 during mid-day trading on Thursday, reaching $426.57. The company had a trading volume of 3,661,206 shares, compared to its average volume of 1,736,253. The firm has a 50 day moving average of $489.25 and a 200 day moving average of $528.84. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 12 month low of $409.85 and a 12 month high of $627.88. The company has a market capitalization of $161.03 billion, a PE ratio of 25.81, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is currently 10.41%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $13,106,062 in the last three months. 0.34% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on TMO shares. Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research report on Thursday. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research report on Thursday. Scotiabank raised their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a report on Monday, February 3rd. Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Finally, The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $618.68.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.